Setting and Participants
Patients between 18 and 75 years old who met the inclusion criteria were recruited into the study. They all voluntarily participated and signed the informed consent form. The admission criteria were consistent with primary bilateral CRSwNP from the EPOS 2020 guidelines5. Patients who had poor control of nasal symptoms after 6-12 weeks of drug therapy and needed surgical intervention were enrolled. Secondary CRS were excluded. Pregnant or breastfeeding women were not included in the study.
All patients were registered in the inpatient department from March 2020 to January 2021 and were randomly assigned to three groups. Patients in control group received conventional treatment (antibiotics for 3 days and nasal corticosteriod and irrigation for 1 month) and placebo (saline) nasal-spray twice per day after ESS. In the rh-bFGF nasal-spray group, patients received conventional treatment and rh-bFGF nasal-spray after ESS (4 sprays (1 spray=0.1 ml) twice per day). In the rh-bFGF nasal-drop group, patients received conventional treatment and rh-bFGF nasal-drops (0.4 ml twice per day). The patients in rh-bFGF nasal-drop group were required to keep the posture of Mygind during nasal-drops17. All enrolled patients received rh-bFGF treatment for 1 month and were followed up for 1 year.